WHO naming stem · suffix · 11 listed names
-prim
This page was written with AI.
antibacterials, dihydrofolate reductase (DHFR) inhibitors, trimethoprim analogues
Where it sits in a name
WHO writes the stem as -prim. So the letters prim sit at the end of the name (…prim).
All 11 names WHO lists under -prim
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 1 of 11 names appears in these lists: 1 in the US list (FDA Drugs@FDA) and 0 in the EU central list (EMA); 1 has national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- aditoprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- baquiloprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- brodimoprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- epiroprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- iclaprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- metioprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- ormetoprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- talmetoprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tetroxoprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- trimethoprimUS brands: PRIMSOL (discontinued in FDA listings), PROLOPRIM (discontinued in FDA listings), TRIMPEX (discontinued in FDA listings), TRIMPEX 200 (discontinued in FDA listings)in combination: BACTRIM with sulfamethoxazole; BACTRIM DS with sulfamethoxazole; SULFATRIM PEDIATRIC with sulfamethoxazole; BACTRIM PEDIATRIC (discontinued in FDA listings) with sulfamethoxazole; COTRIM (discontinued in FDA listings) with sulfamethoxazole; COTRIM D.S. (discontinued in FDA listings) with sulfamethoxazole; POLYTRIM (discontinued in FDA listings) with polymyxin b; SEPTRA (discontinued in FDA listings) with sulfamethoxazole; SEPTRA DS (discontinued in FDA listings) with sulfamethoxazole; SEPTRA GRAPE (discontinued in FDA listings) with sulfamethoxazole; SULFAMETHOPRIM (discontinued in FDA listings) with sulfamethoxazole; SULFAMETHOPRIM-DS (discontinued in FDA listings) with sulfamethoxazole
10 more
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (discontinued in FDA listings) with sulfamethoxazole; SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH (discontinued in FDA listings) with sulfamethoxazole; SULFATRIM (discontinued in FDA listings) with sulfamethoxazole; SULFATRIM-DS (discontinued in FDA listings) with sulfamethoxazole; SULFATRIM-SS (discontinued in FDA listings) with sulfamethoxazole; SULMEPRIM (discontinued in FDA listings) with sulfamethoxazole; SULMEPRIM PEDIATRIC (discontinued in FDA listings) with sulfamethoxazole; TRIMETH/SULFA (discontinued in FDA listings) with sulfamethoxazole; UROPLUS DS (discontinued in FDA listings) with sulfamethoxazole; UROPLUS SS (discontinued in FDA listings) with sulfamethoxazoleEU (central) brands: none found - vaneprimNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Same group, without the stem
WHO also lists this name under -prim: group (c) of Part IV of the 2024 stem book, “INN which belong to the same group of pharmaceutical substances but in which the stem is not used”. It belongs to the same group of substances as the group (a) names above, yet it does not carry -prim, so the name alone does not reveal the group.
- diaveridine
Decode another name
Decoded
iclaprim
Listed INNCarries the WHO stem -prim
- -primend of the nameWHO lists it hereWHO definition: antibacterials, dihydrofolate reductase (DHFR) inhibitors, trimethoprim analogues
“iclaprim” is an INN that WHO lists under -prim in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -prim (Part II B) and the 11 names (Part IV, group (a)), and the 1 of the same group without the stem (group (c)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.